Hinova Pharmaceuticals Inc. has synthesized prodrugs of orforglipron (a glucagon-like peptide 1 receptor [GLP-1R] agonist) for the potential treatment of diabetes, obesity, hypertension, arteriosclerosis, cerebral infarction, arthritis, polycystic ovary syndrome and Parkinson’s disease, among others.